Sei sulla pagina 1di 4

Ending Aging :

INTRODUCING

Project|21
HUMAN CLINICAL TRIALS FOR REJUVENATION BIOTECHNOLOGIES

from SENS Research Foundation


World populations are aging, and the social and economic burdens of age-related disease are
rising steeply. For an increasing number of elderly individuals, healthcare is too often reduced
to crisis management in the emergency room, painfully harsh treatments for diseases such as
cancer, or best efforts at palliative care.
SENS Research Foundation exists to end aging. Since 2009 we have worked to make the concept of
rejuvenation biotechnology the repairing of the damage which occurs to our bodies as we age into a
reality.
Our research, education and awareness programs have created the foundations of the Rejuvenation
Biotechnology Industry, an industry that will be capable of targeting the diseases of aging with genuine,
effective, affordable cures. It is time for the Foundation to partner with a new generation of visionary
philanthropists, to build this revolutionary industry. Now, with your help, we can bridge the most
challenging gulf between research and treatment: we can deliver human clinical trials.

Introducing Project|21
Through Project|21 we will be able to deliver human clinical trials of rejuvenation
biotechnologies by 2021.
Ending aging will require large-scale investment to flow into a globally-recognized industry for
rejuvenation biotechnology. We have put all the pieces in place core research groups, key players, shared
knowledge, underlying toolsfor the creation of this industry.
Now, through three new Foundation programs, Project|21 will deliver the perfect environment for the
critical marriage of opportunity and investment. With proper stewardship of this emerging industry, we
can create an environment where the first damage repair interventions addressing specific age-related
diseases will be brought to human clinical trials within five years.
Project|21 will require $50 million in total funding, at least half of which will come from the members of
SENS Research Foundations Group|21. Group|21 will bring together 21 philanthropists, each donating
between $500,000 and $5 million. Grants, grassroots efforts, and matching-fund strategies will provide the
remaining support.

Preparing the Groundwork


S E N S R E S E A R C H F O U N D AT I O N , S I N C E 2 0 0 9
Since its founding, SENS Research Foundation has
achieved a number of firsts. It is the first organization to
build a research program around a clear framework for the
underlying causes of aging; the first to fund collaborative
research based on this framework; the first to attract multi-
million-dollar annual funding for rejuvenation technologies
from philanthropic supporters; and the first to establish a
global network of rejuvenation biotechnology experts,
from which are drawn the members of the Foundations
world-class Research Advisory Board.
Our Research Program directs internal research at our
own facility in Mountain View, CA and funds programs
at a diverse range of top-tier institutions. We support
the first true generation of rejuvenation biotechnology

professionals, through the research opportunities afforded


to students under our Education Program. Our Awareness
Program reaches a wide audience of individuals and
institutions through talks and conferences, backed by
press, broadcast and social media.
The success of this work has driven early-
stage
discoveries, the emergence of new pioneers in
rejuvenation biotechnology, and widespread support for
our approach. We have created intellectual property,
fostered biotechnology companies, and built the
network of professionals with knowledge and experience
in rejuvenation biotechnology. Together, these
accomplishments have laid the groundwork for the rapid
growth of the next generation of biotechnology.

Group|21:
L E A D E R S H I P, E N G A G E M E N T, P A R T N E R S H I P
Philanthropic giving should open a dialogue between donor and recipient which goes
beyond a financial transaction. Through engagement philanthropy we seek to develop
individual, tailored relationships with our Group|21 and other supporters, providing them
with the opportunity to integrate fully into our network, not just with regular e-mail
updates, but with regional meetings, project reviews, and investment analyses.
Project|21 has been carefully designed to pair this engagement philanthropy with the
strongest elements of venture philanthropy: flexible funding models, programs designed
to evolve into self-supporting efforts, and solid investment in core facilities. This hybrid
model is woven into the structure of the Project|21 programs.

Our leadership team knows that the decision to invest in a non-profit is not one made
l i g h t l y, a n d r e q u i r e s a p e r s o n a l r e l a t i o n s h i p b a s e d o n t r a n s p a r e n c y a n d t r u s t .

Michael Kope Chief Executive Officer and Co-founderreceived his J.D. from the University of Michigan in 1990. He has served
as the University of Michigans Intellectual Property Counsel, Director of Corporate Development for Aviron and MedImmune,
and CEO and officer of a number of biotechnology start-ups.
Aubrey de Grey, Ph.D. Chief Science Officer and Co-founderreceived his Ph.D. in Biology from the University of Cambridge
in 2000. He is Editor-in-Chief of Rejuvenation Research, is a Fellow of both the Gerontological Society of America and the
American Aging Association, and sits on the editorial and scientific advisory boards of numerous journals and organizations.
Michael and Aubrey are supported by the staff of SENS Research Foundation and by the twenty-six field-leading scientists on our
Research Advisory Board who help guide our research strategy.

2016 and Beyond:


A THREE-PART PLAN FOR HUMAN CLINICAL TRIALS
Today, however, we see three major barriers to the development of truly
effective rejuvenation therapies. First, and of primary importance, funding to
convert promising basic research programs into solid investment candidates
is scarce. Second, there are too few opportunities for dynamic collaborations
with mainstream regenerative medicine. Finally, there is little understanding
of the regulatory pathways and clinical infrastructure these technologies will
require. Under Project|21 we will launch three new programs specifically
designed to address these challenges:
A Project|21 Bridge Fund ($15 million over five years), closing the gap
between research and development capital:
Securing early stage funding in biotech is already difficult, and early bridge
funding for the translation of rejuvenation therapies is in many cases non-
existent. The Project|21 investment program will fund up to ten projects per
year. With careful targeting of promising early-stage technologies made in
collaboration with life science investment groups we will accelerate the
translation of the first rejuvenation technologies to private markets, and
assist in launching the rejuvenation biotechnology industry. Notably, this
program can also help create a continuous and self-sustaining funding
stream for our work.
A Center of Excellence ($10 million over five years), delivering better
opportunities for collaborative development:
Housed at a major institution in regenerative medicine and aging research,
a new Center of Excellence in Rejuvenation Biotechnology would afford
better opportunities for collaborative development of our next-generation
research programs. The Center will enable new, highly-
collaborative
projects to further our research goals, break down barriers to the adoption of
rejuvenation research strategies, and help create a pipeline of translational
opportunities.
An Alliance Program ($5 million over five years), providing pathways
for the regenerative medicine community for the development of
rejuvenation biotechnologies:
The Foundation has already been instrumental in creating the CASMI
Translational Stem Cell Consortium (CTSCC), an organization that has
successfully assembled collaborative efforts between academia and
industry for the common good of stem cell therapeutic development. Using
the CTSCC model and guided by its founding director, the Rejuvenation
Biotechnology Alliance Program will address challenges in regulation,
manufacturing, and investment.
These programs will be critical to meeting our clinical trial goal. Combined
with the best of our existing research, education and awareness programs
($20 million over five years), they will provide opportunities for meaningful
and measurable results in terms of funding opportunities, translational
progress, and growth of infrastructure, throughout the five-year process.

Rejuvenation
Biotechnologies
Many things go wrong with aging bodies,
but at the root of them all is the burden
of decades of unrepaired damage to
the cellular and molecular structures
that make up the functional units of our
tissues.
In contrast, rejuvenation
biotechnologies are targeted therapies
that apply the principles of regenerative
medicine to the entire scope of the
damage of aging. These damage-
repair therapies will restore the normal
functioning of our bodies cells and
essential biomolecules, preventing age-
related disease.
Instead of merely slowing down the
accumulation of aging damage in our
tissues, rejuvenation biotechnologies
will remove, repair, replace or render
harmless our damaged cellular and
molecular machinery, returning aging
tissues to health.

SENS Research Foundation has always looked to a wide community for support for its
vision of a world free from the diseases of aging.
Today we look to you to join us in Project|21, as donors and partners. Contribute to our
strategic planning, board recruitment, capital programs, network growth, and expanding
industry networks.

Help us make genuine cures for


age-related disease a reality.

For inquiries please contact:

John de Michele at 760-840-7335 or john.demichele@sens.org.

110 Pioneer Way, Suite J


Mountain View, CA 94041
www.sens.org